The MarCom Journal
SEE OTHER BRANDS

Your media and advertising news reporter

The MarCom Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The MarCom Journal.

Press releases published on June 2, 2025

Aura Minerals Agrees to Acquire the Mineração Serra Grande Gold Mine in Goiás, Brazil

Aura Minerals Agrees to Acquire the Mineração Serra Grande Gold Mine in Goiás, Brazil

ROAD TOWN, British Virgin Islands, June 02, 2025 (GLOBE NEWSWIRE) -- Aura Minerals Inc. (TSX: ORA, B3: AURA33 and OTCQX: ORAAF) (“Aura” or the “Company”) is pleased to announce that Aura, AngloGold Ashanti plc (“AngloGold”) and a wholly owned subsidiary of …

Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera’s target product profile, significantly derisking program and further validating its oral, biologics-like profile >90% mean STAT6 degradation in blood achieved at all …

Big Names & Fresh Faces Headline Rogers Sports & Media’s Canadian Originals Slate for HGTV and Food Network 

Big Names & Fresh Faces Headline Rogers Sports & Media’s Canadian Originals Slate for HGTV and Food Network 

– Rogers Sports …

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

– Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms – – Generally well-tolerated with low rates of adverse events and discontinuation – – Brilaroxazine improved multiple neuroinflammatory markers …

De grands noms et de nouveaux visages dans les productions originales canadiennes de Rogers Sports & Média sur HGTV et Food Network 

De grands noms et de nouveaux visages dans les productions originales canadiennes de Rogers Sports & Média sur HGTV et Food Network 

– Rogers Sports …

Vanguard Food LP Announces Closing of Transaction to Create Emerging Leader in North American Produce Industry

Vanguard Food LP Announces Closing of Transaction to Create Emerging Leader in North American Produce Industry

– Transaction creates new joint-venture in the North American produce industry backed by private investment firms – – Parties intend to provide additional capital to execute a roll-up strategy of other produce assets and operations – LAKE MARY, Fla., June …

Asante Receives Second US$100 Million Advance From Fujairah, Provides Interim Financing Update

Asante Receives Second US$100 Million Advance From Fujairah, Provides Interim Financing Update

VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Asante Gold Corporation (CSE: ASE | GSE: ASG | FRANKFURT:1A9 | U.S.OTC: ASGOF) (“Asante” or the “Company”) is pleased to announce that it has received the second US$100 million advance from …

Coda Octopus Group Sets Fiscal Second Quarter 2025 Earnings Conference Call for Monday, June 16, 2025, at 10 a.m. Eastern Time

Coda Octopus Group Sets Fiscal Second Quarter 2025 Earnings Conference Call for Monday, June 16, 2025, at 10 a.m. Eastern Time

Orlando, FL, June 02, 2025 (GLOBE NEWSWIRE) -- Coda Octopus Group, Inc. (“CODA” or the “Company”) (NASDAQ: CODA), a global market leader in real-time 3D/4D/5D and 6D imaging sonar technology for real-time subsea intelligence and new generation augmented …

Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass

Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass

Trial demonstrated that approximately 35% of semaglutide-induced weight loss was due to loss of lean mass Combining semaglutide with muscle-preserving antibodies protected lean mass – sparing approximately 50%-80% of the lean mass lost with semaglutide …

NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury

NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury

Study met its primary endpoint by achieving statistical significance on one of its two pre-specified co-primary endpoints, demonstrating increased electrical connectivity between the brain and hand muscle in individuals with a cervical level spinal cord …

Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

- Bosakitug is a Potential Best-in-Class Investigational Monoclonal Antibody with Demonstrated Superior Potency, Residence Time, and Affinity to Thymic Stromal Lymphopoietin (TSLP) - - Top Line Results Expected in the Second Half of 2026 - WAYNE, Pa., June …

SAIC Announces First Quarter of Fiscal Year 2026 Results

SAIC Announces First Quarter of Fiscal Year 2026 Results

Revenues of $1.88 billion; approximately 2% revenue growth Net bookings of $2.4 billion; book-to-bill ratio of 1.3 Net income of $68 million; Adjusted EBITDA(1) of $157 million or 8.4% of revenues Diluted earnings per share of $1.42; Adjusted diluted …

Cancer mRNA Vaccine Clinical Trials FDA Approval mRNA Therapies Clinical Advances Insight

Cancer mRNA Vaccine Clinical Trials FDA Approval mRNA Therapies Clinical Advances Insight

Delhi, June 02, 2025 (GLOBE NEWSWIRE) -- mRNA cancer vaccines approach clinical maturity, the commercial landscape surrounding them is rapidly changing. Over 60 candidates in the works, with a few in Phase III clinical trials, the industry is increasingly …

Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema

Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema

Deucrictibant data shows single-dose durability without symptom reoccurrence in the majority of HAE attacks treated First-ever bradykinin B2 receptor mechanism-on-mechanism prophylactic/on-demand data supports potential for deucrictibant portfolio …

Patagonia Gold Announces Completion of US$40 Million Investment Into Its Calcatreu Project

Patagonia Gold Announces Completion of US$40 Million Investment Into Its Calcatreu Project

VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Patagonia Gold Corp. (“Patagonia” or the “Company”) (TSXV: PGDC) is pleased to announce that, further to its news releases dated March 14, 2025, April 14, 2025 and May 20, 2025, it has …

Codere Online Announces Filing of 2024 Annual Report on Form 20-F

Codere Online Announces Filing of 2024 Annual Report on Form 20-F

Luxembourg, Grand Duchy of Luxembourg, June 2, 2025 (GLOBE NEWSWIRE) – Codere Online Luxembourg, S.A. (Nasdaq: CDRO / CDROW) (the “Company” or “Codere Online”), a leading online gaming operator in Spain and Latin America, today announced that it has filed …

BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types

BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types

BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set a new standard of care in multiple tumor types The co- …

Brazil Potash Year to Date Summary: Company Achieves Milestones, Advancing Strategic Autazes Project Further Towards Construction

Brazil Potash Year to Date Summary: Company Achieves Milestones, Advancing Strategic Autazes Project Further Towards Construction

Achievements Include Commercial Agreements, World-Class Board Appointments, Construction Progress, and Enhanced Capital Access Management to Attend Wells Fargo Industrials Conference on June 10, 2025, in Chicago MANAUS, Brazil, June 02, 2025 (GLOBE …

Castellum, Inc. to Participate in the “2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow” Virtual Conference Presented by Maxim Group LLC on Tuesday, June 3rd – Thursday, June 5th at 9:00 a.m. EDT

Castellum, Inc. to Participate in the “2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow” Virtual Conference Presented by Maxim Group LLC on Tuesday, June 3rd – Thursday, June 5th at 9:00 a.m. EDT

VIENNA, Va., June 02, 2025 (GLOBE NEWSWIRE) -- Castellum, Inc. (NYSE-American: CTM) announces that its Chief Executive Officer, Glen Ives, has been invited to present at the “2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow,” …

Gaza children stand in the palm of memory

Gaza children stand in the palm of memory

(MENAFN) In the devastated Tel al-Hawa area, located on the western edge of Gaza City, traces of childhood remain scattered beneath the tattered fabric of a makeshift shelter. Fourteen-year-old Kamal Mahdi sits curled up on damp blankets, his slender …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service